临床试验/NCT05170685

NCT05170685No Longer Available不适用

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab

Bristol-Myers Squibb0 个研究点开始时间: 2021年12月28日最近更新: 2022年4月28日

试验速览

阶段: 不适用
状态: No Longer Available
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

研究设计

研究类型: Expanded Access

入排标准

入选标准

未提供

排除标准

未提供

研究者

发起方

Bristol-Myers Squibb

申办方类型

Industry

责任方

Sponsor

相似试验

No Longer Available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenSquamous Non-Small Cell Lung CancerNon-squamous Non-Small Cell Lung Cancer

NCT02475382Bristol-Myers Squibb

No Longer Available

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic MelanomaMalignant Melanoma

NCT02186249Bristol-Myers Squibb

EXPANDED ACCESS PROGRAM WITH NIVOLUMAB FOR SUBJECTS WITH HISTOLOGICALLY CONFIRMED STAGE III (UNRESECTABLE) OR STAGE IV MELANOMA PROGRESSING POST PRIOR SYSTEMIC TREATMENT CONTAINING AN ANT-CTLA-4 MONOCLONAL ANTIBODY.-C439 Malignant melanoma of skin, unspecifiedMalignant melanoma of skin, unspecifiedC439

PER-012-15BRISTOL MYERS SQUIBB COMPANY,

No Longer Available

Expanded Access Program With Nivolumab to Treat MelanomaStage III (Unresectable) or Stage IV Advanced Melanoma

NCT02142218Bristol-Myers Squibb

Expanded Access Program with Nivolumab (ONO-4538) for malignant non-pleural mesothelioma (VIOLA)Malignant MesotheliomaNivolumabMesothelioma

JPRN-jRCT2051220186Kijima Takashi15